JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:1754-1768, doi:10.1016/j.jacc.2005.12.051 (Published online 17 April 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serruys, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serruys, P. W.

Fourth Annual American College of Cardiology International Lecture

A Journey in the Interventional Field

Patrick W. Serruys, MD, PhD, FESC, FACC*

Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.


Figure 1
View larger version (21K):

[in a new window]
  		Figure 1 The rosy prophecy. ARTS = Arterial Revascularization Therapies Study; CABG = coronary artery bypass graft; CABRI = Coronary Angioplasty versus Bypass Revascularization Investigation; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty.

 

Figure 2
View larger version (114K):

[in a new window]
  		Figure 2 Endothelial progenitor cell capture stent. (A) Bare stent; (B) coated stent.

 

Figure 3
View larger version (36K):

[in a new window]
  		Figure 3 (A) Normal mechanism of vessel stress; (B) effect of a device eluting nitric oxide. SMC = smooth muscle cell.

 

Figure 4
View larger version (39K):

[in a new window]
  		Figure 4 Where we have come from and where we are going: the next innovative steps in vascular intervention.

 

Figure 5
View larger version (43K):

[in a new window]
  		Figure 5 The "new diagnostic world" of the vulnerable plaque.

 

Figure 6
View larger version (97K):

[in a new window]
  		Figure 6 (A) Angiographic image of an intermediate lesion in the proximal right coronary artery; (B) corresponding multislice computed tomographic image of the lesion (vertical view); (C) corresponding multislice computed tomographic image of the lesion (horizontal view); (D) enlarged view of the clacified plaque in panel C; and (E) corresponding intravascular ultrasonic image of the calcified plaque. AV = atrioventricular.

 

Figure 7
View larger version (26K):

[in a new window]
  		Figure 7 Multislice computed tomography (MSCT) plaque burden: an ubiquitous phenomenon. Results: distribution of any plaque-% (large plaque-%). LCA = left coronary artery; RCA = right coronary artery.

 

Figure 8
View larger version (34K):

[in a new window]
  		Figure 8 Diagnostic value of palpography. CRP = C-reactive protein; ROC = receiver-operating characteristic.

 

Figure 9
View larger version (99K):

[in a new window]
  		Figure 9 Virtual histology or ... how to convert an ex vivo (pressurized) intravascular ultrasound image into a color-coded histological cross section. (A) Intravascular ultrasound cross section; (B) in vivo virtual histology color-coded of same cross section; (C) ex vivo histology of same cross section; (D) color pencil sketch of ex vivo histology cross section.

 

Figure 10
View larger version (74K):

[in a new window]
  		Figure 10 Optical coherence tomography showing detailed three layer resolution of a coronary vessel.

 

Figure 11
View larger version (130K):

[in a new window]
  		Figure 11 (A) Optical coherence tomography showing thin cap fibrous atheroma and (B and C) intramuscular capillary.

 

Figure 12
View larger version (22K):

[in a new window]
  		Figure 12 Vulnerable plaque triage. CRP = C-reactive protein; DES = drug-eluting stents; EEM = external elastic membrane.

 

Figure 13
View larger version (61K):

[in a new window]
  		Figure 13 Phantom made of cryogel mimicking a total occlusion of which the cross section is seen by a forward-looking (60°) optical coherence imaging wire (0.014 inch). OCT = optical coherence tomography.

 

Figure 14
View larger version (127K):

[in a new window]
  		Figure 14 Has the myocardium its own stem cells? Arrows = C-Kit+ cells. C-Kit is an antigen of staminality. Its expression is a proof of staminal potential of these cells. These cells are still uncommitted. Arrowheads = cells expressing MEF2C. MEF2C is a transcription factor expressed early in the myocyte lineage. These cells are committed early to myocyte lineage. *Alpha-sarcomeric actin. This cell is engaged in a more advanced stage of myocyte lineage. Reprinted, with permission, from Beltrami et al. (66).

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.